293 related articles for article (PubMed ID: 33490659)
1. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?
Nagoor Meeran MF; Seenipandi A; Javed H; Sharma C; Hashiesh HM; Goyal SN; Jha NK; Ojha S
Heliyon; 2021 Jan; 7(1):e05703. PubMed ID: 33490659
[TBL] [Abstract][Full Text] [Related]
2. β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.
Jha NK; Sharma C; Hashiesh HM; Arunachalam S; Meeran MN; Javed H; Patil CR; Goyal SN; Ojha S
Front Pharmacol; 2021; 12():590201. PubMed ID: 34054510
[TBL] [Abstract][Full Text] [Related]
3. Can
Nagoor Meeran MF; Javed H; Sharma C; Goyal SN; Kumar S; Jha NK; Ojha S
Heliyon; 2021 Feb; 7(2):e05990. PubMed ID: 33585706
[TBL] [Abstract][Full Text] [Related]
4. CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections.
Nagoor Meeran MF; Sharma C; Goyal SN; Kumar S; Ojha S
Drug Dev Res; 2021 Feb; 82(1):7-11. PubMed ID: 33190277
[TBL] [Abstract][Full Text] [Related]
5. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
Khursheed A; Jain V; Rasool A; Rather MA; Malik NA; Shalla AH
Microb Pathog; 2021 Aug; 157():104933. PubMed ID: 33984466
[TBL] [Abstract][Full Text] [Related]
6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
Stratton CW; Tang YW; Lu H
J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
[TBL] [Abstract][Full Text] [Related]
10. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
11. The landscape of potential health benefits of carotenoids as natural supportive therapeutics in protecting against Coronavirus infection.
Lu LW; Gao Y; Quek SY; Foster M; Eason CT; Liu M; Wang M; Chen JH; Chen F
Biomed Pharmacother; 2022 Oct; 154():113625. PubMed ID: 36058151
[TBL] [Abstract][Full Text] [Related]
12. Potential health benefits of zinc supplementation for the management of COVID-19 pandemic.
Oyagbemi AA; Ajibade TO; Aboua YG; Gbadamosi IT; Adedapo ADA; Aro AO; Adejumobi OA; Thamahane-Katengua E; Omobowale TO; Falayi OO; Oyagbemi TO; Ogunpolu BS; Hassan FO; Ogunmiluyi IO; Ola-Davies OE; Saba AB; Adedapo AA; Nkadimeng SM; McGaw LJ; Kayoka-Kabongo PN; Oguntibeju OO; Yakubu MA
J Food Biochem; 2021 Feb; 45(2):e13604. PubMed ID: 33458853
[TBL] [Abstract][Full Text] [Related]
13. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
14. Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19.
Xiang J; Lu M; Shi M; Cheng X; Kwakwa KA; Davis JL; Su X; Bakewell SJ; Zhang Y; Fontana F; Xu Y; Veis DJ; DiPersio JF; Ratner L; Sanderson RD; Noseda A; Mollah S; Li J; Weilbaecher KN
J Virol; 2022 Apr; 96(7):e0005722. PubMed ID: 35319225
[TBL] [Abstract][Full Text] [Related]
15. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
16. An overview of possible pivotal mechanisms of Genistein as a potential phytochemical against SARS-CoV-2 infection: A hypothesis.
Jafari A; Esmaeilzadeh Z; Khezri MR; Ghasemnejad-Berenji H; Pashapour S; Sadeghpour S; Ghasemnejad-Berenji M
J Food Biochem; 2022 Oct; 46(10):e14345. PubMed ID: 35866873
[TBL] [Abstract][Full Text] [Related]
17. Potential of 24-Propylcholestrol as Immunity Inducer against Infection of COVID-19 Virus:
Kurnia D; Wiani I; Zainuddin A; Windaryanti D; Sondang Gabriel C
Comb Chem High Throughput Screen; 2023; 26(2):383-391. PubMed ID: 35538835
[TBL] [Abstract][Full Text] [Related]
18. Plausibility of natural immunomodulators in the treatment of COVID-19-A comprehensive analysis and future recommendations.
Akter R; Rahman MR; Ahmed ZS; Afrose A
Heliyon; 2023 Jun; 9(6):e17478. PubMed ID: 37366526
[TBL] [Abstract][Full Text] [Related]
19. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
20. An exhaustive comprehension of the role of herbal medicines in Pre- and Post-COVID manifestations.
Prajapati SK; Malaiya A; Mishra G; Jain D; Kesharwani P; Mody N; Ahmadi A; Paliwal R; Jain A
J Ethnopharmacol; 2022 Oct; 296():115420. PubMed ID: 35654349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
